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ABSTRACT
Objectives: High-risk types of human papillomavirus (HPV) are strongly associated with cervical 
cancer (CC), and Chlamydia trachomatis (CT), the most frequent sexually transmitted 
bacterial infection (STBI) worldwide, seems to be a risk factor for HPV infection and for CC. It is 
also known that both agents are more prevalent in vulnerable communities where lack of adequate 
primary health care is a cause for concern. The aim of this work was to determine the impact of CT 
and HPV infections in women belonging to an isolated aboriginal population (Pilaga community) 
from a poor region in Northern Argentina (province of Formosa). For this purpose, a cross-sectional 
study was performed in all sexually active Pilaga women, who attended a local community-based 
gynecological health screening project. The polymerase chain reaction (PCR) method on a cervi-
cal brush specimen was used to detect both agents. Results: A total of 227 women (20% of the total 
female population of the Pilaga community) were studied and the overall prevalence was 26.4% 
for CT, 46.7% for HPV and 16.3% for concurrent infection. CT infection was higher in HPV DNA 
positive (34.2%) than in HPV DNA negative women (19%; OR: 2.22/95% CI = 1.16-4.28 / p = 0.009) 
and the most prevalent HPV types were HPV-16 (19.4%), 6 and 18 (5.3%), 58 (3.5%) and 33 (3.1%). 
Conclusions: The prevalence of CT and HPV observed in Pilaga women are among the worst regis-
tered in Latin America. Also, data collected suggest that chlamydial infection may play an important 
role in the natural history of HPV infection. On this respect, we propose that the association between 
these two agents seems to be more related to a mutual potentiation than to the fact that they share a 
common route of transmission.
Keywords: Chlamydia trachomatis; papillomavirus infections; indigenous population; uterine cervi-
cal diseases.
INTRODUCTION
Chlamydia trachomatis (CT) is the most fre-
quent sexually transmitted bacterial infection 
(STBI) worldwide, with an estimated 89 million 
new cases per year.1,2 Up to 70% of such infec-
tions are asymptomatic and the detection of 
cases has an important epidemiological implica-
tion, because the main consequences (infertility, 
ectopic pregnancy, pelvic inflammatory disease 
and perinatal infections) of symptomatic and 
asymptomatic infections are often identical.2,3 
Although many authors refer to an association 
between CT infection and dysplastic or neoplas-
tic cervical atypia, epidemiological data have 
not yet provided consistent evidence about its 
real implication in cervical cancer (CC) devel-
opment.4-6 However, the asymptomatic nature 
of CT infection, its long-term persistence in 
the absence of treatment, and its capability of 
inducing metaplasia and chronic inflamma-
tion are well-defined characteristics to strongly 
consider this bacteria as a potential cofactor for 
high-risk persistent HPV infection (the main 
proven cause of CC).7-9 HPV genital infection 
is highly frequent worldwide and its prevalence 
in the general population ranges from 2-44% 
depending on the region of the world.10 How-
ever, it is known that most HPV infections are 
transient and only a small proportion of women 
with high-risk persistent HPV infection will 
develop CC.11-13 Therefore, numerous cofactors 
that might promote virus persistence or enhance 
its oncogenicity have been studied in recent dec-
ades to better understand the oncogenic pro-
cess.14,15 CT is one of these cofactors.4,8,9
The annual mortality rate for CC in Ar-
gentina is 7.8/100,000 women, but this rate is 
three times higher in the northeastern region Este é um artigo Open Access sob
 a licença de CC BY-NC-ND
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of the country,16 where a wide spectrum of Indian and iso-
lated white communities live in unfavorable socioeconomic 
and health conditions. 
The aim of this study was to determine the prevalence 
of CT and HPV infections among vulnerable populations of 
native Indians belonging to the Pilaga community in north-
ern Argentina.
METHODS
Study population
This study was nested in a community-based gyneco-
logical health screening project for the Pilaga aboriginal 
people of the central region of Formosa province (north-
ern Argentina). Two hundred and twenty-seven women 
aged 13-68 years (mean age 30 years), corresponding to 
20% of all sexually active women of the Pilaga Indians 
in Argentina, were recruited from different aboriginal 
settlements between March 2007 and March 2009. 
A standardized questionnaire was used to interview the 
subjects regarding their clinical history, sexual behavior, 
cultural habits and socio-economic and living conditions. 
After providing informed consent, all women were exam-
ined by a gynecologist. 
The study was reviewed and approved by the Ethics 
Committee of the Institute of Regional Medicine of North-
east National University, Argentina.
Sample collection and DNA extraction
Cervical exfoliated cells were collected from all women by 
sampling the ecto- and endocervix using a wooden spatula 
for PAP smears and a cytobrush for HPV and CT DNA de-
tection. Cervical cells from the latter were eluted in sterile 
phosphate-buffered saline (PBS) contained in a tube, and 
then transported on ice to the processing laboratory. Upon 
arrival to the lab and after checking the sample container’s 
integrity, the cells of each sample were pelleted by centrifu-
gation and kept frozen at -70°C until processing.
DNA was obtained by treating pellets with 400-700 µL 
of homogenization solution (2% cetyltrimethylammonium 
bromide-CTAB, 1.4 M NaCl, 0.2% β-mercaptoethanol, 
20 mM EDTA, 100 mM Tris-HCl pH 5.0), extracted with 
chloroform isoamyl alcohol method, then precipitated 
with absolute ethanol and resuspended in 50-100 μL of ster-
ile double-distilled water. All samples were checked to assess 
DNA quality and integrity by amplifying a known region 
of the human β-globin gene (268 bp). The samples negative 
for the β-globin test were discarded.
Cytological analysis
PAP smears were processed and analyzed according to the 
2001 Bethesda Classification System. The final diagnosis was 
based on the worst morphological picture.
CT and HPV DNA amplification 
CT DNA was detected in cervical samples by polymerase 
chain reaction (PCR) using the KL1/KL2 primers, as pre-
viously described.17 This primer pair amplifies a 241 bp 
fragment of the chlamydial multicopy, and a genetically 
conserved, cryptic plasmid. PCR was performed in a final 
volume of 20 µL using 3 µL of DNA sample; 10 mM Tris-
HCl pH = 8.3, 50 mM KCl, 3.5 mM MgCl2, 5 nmol of each 
deoxyribonucleoside triphosphate (dNTP), 20 pmol of 
each primer, 1.25 U Taq DNA polymerase (Go-Taq® DNA 
polymerase, Promega, USA). Each amplification reaction 
was carried out as follows: an initial cycle at 93°C for 3 min; 
35 cycles of 1 min at 93°C, 1 min at 64°C and 1 min at 
72°C and a final extension at 72°C for 5 min. Finally, the 
PCR products were electrophoresed on a 2% agarose gel, 
stained with ethidium bromide (EB) and photographed 
under UV light.
HPV DNA amplification and typing were conduct-
ed using the widely known MY09/11 PCR (450 bp PCR 
product) followed by the restriction fragment-length poly-
morphism (RFLP) technique, as previously described.18,19 
Briefly, the products of MY09/11 PCR were first electro-
phoresed on a 2% agarose gel, stained with EB and visualized 
under UV light. Then, the amplicons of positive 
samples were digested by seven restriction enzymes 
(BamHI, DdeI, HaeIII, HinfI, PstI, RsaI and Sau3AI) in 
individual microtubes. After that, the RFLP product of 
each sample was electrophoresed on a 3% agarose gel, 
stained with EB, and photographed under UV light. Each 
restriction pattern was compared with published data to 
identify the genotype(s) involved.
Statistical analysis 
Continuous variables were categorized, and the risk 
associated with CT positivity was calculated for each 
category of a variable, adjusted by age. Univariate analysis 
was performed for all variables, and multivariate logistic 
regression analysis was performed in order to identify the 
independent variables that influence the relative risk of 
CT positivity (95% CI). The association between CT and 
HPV infections was evaluated in all women regardless 
of their cytological diagnosis. Data were analyzed using the 
Epi-InfoTM 3.5.1 Statistical Program (Centers for Dis-
ease Control and Prevention, Atlanta, GA) and statistical 
significance was determined by Fisher’s exact test, and 
p-values ≤ 0.05 were considered significant.
RESULTS
The overall prevalence was 26.4% for CT, 46.7% for HPV 
and 16.3% for concurrent infection. The mean crude preva-
lence did not significantly differ from the age-adjusted one. 
The mean frequency of infection, for both agents considered, 
increased with the severity of cervical lesions; however, this 
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was more notorious for HPV infection and particularly for 
high-risk HPV types. The HPV prevalence estimates were 
27.8% in women with normal pap smear, 46.2% in wom-
en with reactive cellular changes (RCC), 87.5% in patients 
with low-grade squamous intraepithelial lesion (L-SIL), and 
100% in patients with high-grade squamous intraepithelial 
lesion (H-SIL) and CC (p < 0.05) (Table 1).
The prevalence of CT infection was significantly higher 
among women with positive HPV DNA (37/106 = 34.9%) 
than among those with negative HPV DNA (23/121 = 19%; 
OR: 2.28, 95% CI = 1.20 - 4.38, p = 0.007). This association re-
mained significant when high- and low-risk HPV types were 
considered separately, as well as infections with one or multi-
Table 1. Chlamydia trachomatis and human papillomavirus infections stratified by grade of cervical status 
among sexually active women of the Pilaga community
Cytology n (%) HPV p High-risk HPV p CT p 
  positive (%)  positive (%)  positive (%)
Negative for SIL  
36 (15.8) 10 (27.8)  7 (19.4)  8 (22.2) 
 
or malignancy 
RCC 173 (76.2) 80 (46.2)  50 (28.9)  47 (27.2) 
L-SIL 16 (7) 14 (87.5) 0.015 12 (75.0) 0.010 5 (31.3) 0.968
H-SIL 1 (0.4) 1 (100)  1 (100)  0 (0) 
CC 1 (0.4) 1 (100)  1 (100)  0 (0) 
Total 227 (100) 106 (46.7)  71 (31.3)  60 (26.4) 
SIL, squamous intraepithelial lesion; RCC, reactive cellular changes; L-SIL, low-grade squamous intraepithelial lesion; H-SIL, high-
grade squamous intraepithelial lesion; ISC, in situ carcinoma.
Table 2. Association between Chlamydia trachomatis and human papillomavirus infections in cervical samples
             Total of women studied      Women with CT DNA positive 
             (n = 227)                              (n = 60)
  n % n % OR (95% CI)
HPV- 121 53.3 23 19 1a
HPV+  106 46.7 37 34.9
 2.28 (1.20 - 4.38)  
      p = 0.007
HPV+ according to risk group     
 High-risk types 71 31.3 24 33.8
 2.18 (1.06 - 4.49) 
      p = 0.021
 Low-risk types 23 10.1 9 39.1
 2.74 (0.95 - 7.83) 
      p = 0.033
 Single HPV infections 78 34.4 26 33.3
 2.13 (1.05 - 4.32) 
      p = 0.022
 Multiple HPV infections 28 12.3 11 39.3
 2.76 (1.04 - 7.28) 
      p = 0.021
a Reference group.
ple viral types (Table 2). Nevertheless, there was no clear asso-
ciation between age, age at first intercourse, number of lifetime 
sexual partners or parity and CT infection. Also, we could not 
evaluate the impact of tobacco or the use of oral contraceptive 
(OC) because only a minor proportion of women referred to 
a smoking habit (3.1%) and less than 6% of women had used 
OC at some point in life. The socio-economic evaluation of 
the living conditions in the Pilaga community showed that the 
majority of participants had completed elementary school 
education (76.8%), but only 27.5% of women had a formal or 
informal occupation at the moment of the study, 98.3% had 
no sanitary latrines in their houses and only 5% had well wa-
ter for drinking and cleaning. 
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The individual prevalence for the 21 different de-
tected HPV types is presented in Figure 1. Among the 
high-risk types, HPV-16 was clearly the most prevalent 
(44/227; 19.4%), followed by HPV-18 (12/227; 5.3%), -58 
(8/227; 3.5%), and -31 and -33 (7/227; 3.1%); while among 
low-risk type, HPV-6 was the most prevalent (12/227; 5.3%), 
followed by HPV-11 (6/227; 2.3%), and -61 and -84 (5/227; 
2.2%). Taking into account all the types found in this series, 
the most frequent were, in order, HPV-16, 18, 6, 58 and 33. 
In addition, 28 infections by multiple HPV types were ob-
served, corresponding to 12.3% of the total women studied. 
According to the data obtained, the only independ-
ent variable associated with CT-DNA positivity was 
concurrent HPV infection.
DISCUSSION
Despite the numerous logistical and cultural barriers that 
hindered this work in the Pilaga population, we were able 
to recruit and study 20% of the sexually active women of the 
community. 
At large, developing countries seem to have higher prev-
alence of CT infections.20 These nations have values that 
range from 5% to 22% in the general population and can 
reach peaks as high as 41% among female adolescents.1,21-24 
On the other hand, in developed countries, the prevalence 
levels range from less than 2% to 8-10% in general popula-
tion and from less than 5% to 20% among female adoles-
cents.1,25 In Argentina, many prevalence studies of CT infec-
tion have been conducted among women, but these studies 
have two important shortcomings: (I) most of them used 
non-standardized populations, different analytical methods 
to detect CT or only considered symptomatic cases; and (II) 
there is scarce epidemiological information about popula-
tions from northern Argentina, the region with the highest 
reported clinical diagnosis of STBI of the country. The avail-
able data show that prevalence ranges from 1.8% to 13% in 
the general population and from 20% to 47% in women with 
gynecological alterations.20,26-28 The overall prevalence of CT 
found in our study (26.4%) is clearly the highest reported in 
Argentina for the general population and is very close to the 
worst prevalence rates worldwide. 
For HPV, the worldwide infection prevalence ranges 
from 2-44% in the general population. Once again, devel-
oping countries usually have the highest prevalence rates.10 
A recent worldwide meta-analysis on global HPV preva-
lence demonstrated an infection rate of 10.4% for the world 
and 12.9% for Latin America,29 and HPV-16 was the most 
common type in both normal and pathological populations. 
In our study, the overall prevalence of HPV was very high 
(46.7%), similar to the values found in developing countries 
with serious problems with implementing and maintaining 
a sustainable gynecological health policy. Also, it is com-
parable with the results obtained by other authors in other 
indigenous populations of northern Argentina (prevalence 
ranging from 52% to 60%), but clearly exceeds the mean 
frequency for populations from the central and southern 
regions of the country and for Latin American women.10,29,30 
In relation to the genotypes found, HPV-16 clearly stands out 
among the 21 different types identified in this work, which 
coincides with worldwide data and with previous studies on 
different populations in Argentina.31-34 In addition, the four 
most prevalent HPV types among Pilaga women (HPV-16, 
18, 6 and -1) represent 70% of all infections detected. These 
are very important baseline data to take into account for fu-
ture post-vaccination epidemiological surveillance. 
It is well-known that CT infection may play a major 
role in the etiology of cervical intraepithelial neoplasia by 
facilitating high-risk HPV entrance and persistence. Prob-
ably, this is due to the chronic inflammation induced by the 
bacteria, and to the resistance to cell apoptosis that persis-
tent CT infections appear to confer. In this respect, our data 
highlight a moderate but significant association between 
concurrent CT and HPV infection. However, due to the 
cross-sectional design of this study, it was not possible to 
determine the primary infection in patients with concur-
rent CT and HPV infections. CT and HPV DNA detection 
by PCR-based assay only indicates an acute or chronic in-
fection in the first case and a transient or persistent HPV 
infection. Nonetheless, the association between these two 
agents seems to be more related to a mutual potentiation 
Figure 1: Prevalence of individual HPV types in cervical 
scrapes among Pilaga women detected by broad-spectrum 
polymerase chain reaction (MY 09/11 PCR) and a restriction 
fragment-length polymorphism assay (RFLP).
aHPV genotypes that could not be defined by the RFLP 
technique.
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than to the fact that they share a common route of trans-
mission.35 In fact, controversial and discordant information 
exists on this topic, and since the role of CT in the natural 
history of HPV infection is not sufficiently clear, this par-
ticular issue merits further study.
CONCLUSIONS
The overall prevalence of CT and HPV infections found 
in this study is very high, even greater than other Latin 
American prevalences. The epidemiological data ob-
tained in this work referred to a specific population, but 
numerous small communities exist in a similar situa-
tion in northern Argentina. One could then suppose that 
similar infection rates prevail requiring effective and sus-
tainable health policies to be implemented. In the case of 
HPV, this is very important in order to prevent CC de-
velopment. For CT, its control is essential for preventing 
pelvic inflammatory disease and infertility. Our data may 
help physicians to prevent diseases in their gynecologi-
cal practices, particularly when dealing with vulnerable 
populations.
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